Anebulo Pharmaceuticals, Inc. (ANEB)

NASDAQ: ANEB · IEX Real-Time Price · USD
3.080
+0.180 (6.21%)
Mar 28, 2024, 3:58 PM EDT - Market closed
6.21%
Market Cap 74.43M
Revenue (ttm) n/a
Net Income (ttm) -10.49M
Shares Out 25.93M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,910
Open 2.990
Previous Close 2.900
Day's Range 2.990 - 3.085
52-Week Range 1.620 - 4.050
Beta -1.03
Analysts Strong Buy
Price Target 6.67 (+116.56%)
Earnings Date May 9, 2024

About ANEB

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 7, 2021
Employees 2
Stock Exchange NASDAQ
Ticker Symbol ANEB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ANEB stock is "Strong Buy." The 12-month stock price forecast is $6.67, which is an increase of 116.56% from the latest price.

Price Target
$6.67
(116.56% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates.

6 weeks ago - Business Wire

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates.

4 months ago - Business Wire

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

6 months ago - Business Wire

Anebulo Pharmaceuticals Announces New CEO

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces New CEO.

6 months ago - Business Wire

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

6 months ago - Business Wire

Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

7 months ago - Business Wire

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

AUSTIN, Texas , May 11, 2023 /PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabi...

11 months ago - PRNewsWire

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

Additional operational efficiencies and opportunities expected with the engagement of Potrero Hill Advisors Sandra Gardiner succeeds Rex Merchant as acting chief financial officer AUSTIN, Texas , Marc...

1 year ago - PRNewsWire

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

1 year ago - Business Wire

Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxi...

1 year ago - Business Wire

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

1 year ago - Business Wire

Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

1 year ago - Business Wire

Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

1 year ago - Business Wire

Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

1 year ago - Business Wire

Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

1 year ago - Business Wire

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

1 year ago - Business Wire

Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

1 year ago - Business Wire

Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants

Anebulo Pharmaceuticals Inc (NASDAQ: ANEB) has announced topline data from Part A of an ongoing Phase 2 trial of ANEB-001 to treat acute cannabinoid intoxication (ACI).  Part A was a 60-subject trial ...

1 year ago - Benzinga

Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

1 year ago - Business Wire

Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

1 year ago - Business Wire

Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

2 years ago - Business Wire

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

2 years ago - Business Wire

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxica...

2 years ago - Business Wire

Anebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals, Inc. ANEB announced financial results for the three months ended December 31, 2021 and recent updates. Q2 2022 Financial Highlights Operating expenses in the second quarter of...

2 years ago - Benzinga